europabio-logoeuropabio-logoeuropabio-logoeuropabio-logo
  • About us
    • Who we are
      • Governance
      • Staff
      • Vacancies
    • What we do
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Cell & Gene Therapies
      • Medicines For Rare Diseases And Children
      • Regulatory Efficiency
      • Biosimilars & Public Procurement
      • Data & Digital
      • Patient Bio-Forum
    • Industrial Biotechnology Council
      • Food, Feed & Nutrition
      • Circular Bioeconomy
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
  • Activities
    • 25 Years of Innovation
    • EFIB 2022
    • European Biotech Week
  • Events
  • Newsroom
    • News & Publications
    • Library
Become a member
✕

Advanced therapy medicinal products: SMEs call for a better investment environment in Europe

07/09/2022
PRESS RELEASE
September 7, 2022, Brussels - EuropaBio, EuropaBio's SME Platform represents Europe’s biotechnology SME community, in close partnership with EuropaBio's National Associations Council, and advocates for innovative biotechnology delivered through SMEs. In May, the SME BioForum organised its inaugural event and invited SME Executives to discuss the business environment for Advanced Therapy Medicinal Products (ATMPs) in Europe.

Please find event conclusions and recommendations HERE.

’’SMEs are key drivers of innovation in Europe. They represent the pipeline through which Europe’s excellence in research is translated and matured, both for patient and economic benefit to Europe. SMEs in the ATMP field face unique challenges related to investment and speed to patients and market. We need to enable these champions of science through a legislative framework that balances competitiveness with delivery to patients, fostering innovation, investment and excellence in Europe. ‘’, said Claire Skentelbery, Director General of EuropaBio.’’

Regulatory pathways
The ATMP development field is fast-evolving. While technology progresses rapidly, national and EU regulators must learn and adapt quickly to support the development and approval of new cell and gene therapies.

Our recommendations:


• Reinforce EMA and national regulatory agency resources to allow for faster approval times
Promote EMA/Member States centres of excellence
• Foster early engagement with national regulatory Authorities
• Simplify GMO requirements for ATMP clinical trials

Market fragmentation
Healthcare systems are very different across Europe. Member States have distinct regulatory practices and experiences that condition how each country and region perceives and assesses value. It is essential to ensure that decision-makers regard ATMP costs as investments in patients, sustainable healthcare systems and society.

Our recommendations:

• Harmonise national requirements for the development of ATMPs
• Greater dialogue on the value and importance of ATMPs
• Adapt Health Technology assessments and consider innovative payment models

Other bottlenecks for growth
ATMP development advances alone do not deliver products to patients. The development pathway requires diverse skills to enable SMEs to succeed in delivering treatment solutions.

Our recommendations:

• Promote ATMP academic and professional development
• Foster partnerships with larger companies and strategic sectors


Next steps
EuropaBio is pleased to invite you to the event presenting policy recommendations and conclusions of both 2022 SME BioForum events (May and October editions) in the field of healthcare and industrial biotechnology on December 13, 11:00-12:15 CET. SAVE THE DATE! For more information about opportunities of participation please contact José Peres, NAC & SME Coordinator.

Advanced therapy medicinal products: SMEs call for a better investment environment in Europe


Download

Share
Alexandra Simionca
Alexandra Simionca

Related posts

06/02/2023

Delivering Europe’s ambitions in rare disease


Read more
31/01/2023

EuropaBio’s 2022 Patient BioForum sets out recommendations to address the challenges of patients with unmet medical needs and calls for multi-stakeholder approach


Read more
17/01/2023

EuropaBio launches SME BioForum in Rare Diseases


Read more
17/01/2023

EuropaBio launches Industry Advisory Group for new Biomanufacturing Platform


Read more

Important links

  • Delivering Europe’s ambitions in rare disease
  • Joint Statement: The Data Act is a leap into the unknown

Categories in our Newsroom

Subscribe for our newsletter

Subscribe to the EuropaBio newsletter to receive the latest news and developments in the Biotech sector!


Subscribe
EuropaBio-Logo-White

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 2600 biotech companies, 2300 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2023 Europabio. All Rights Reserved. Designed by EYAS
Become a member
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies